Table 2.
Clinical studies on efficacy and safety of oral immunotherapy for wheat allergy.
| References | Patients, n | Age, Mean (Range) | Duration Up-Dosing Phase | Duration Manteinance Phase | Target Dose | Efficacy, % Desensitized Pts | Adverse Reaction (% Doses) |
|---|---|---|---|---|---|---|---|
| del Rio et al. 2014 [65] | 6 | 5.5 yrs (5–11) |
3–24 days | 6 months | 12.52 g of wheat protein | 83 | 6.25 (up-dosing phase) |
| Sato et al. 2015 [66] | 18 anaphylactic WA pts | 9 yrs (5.9–13.6) |
5 days | >3 months | 5.2 g of wheat protein |
83.3 | 26.4% (up-dosing phase) |
| Khayatzadeh et al. 2016 [67] | 8 anaphylactic WA pts | 7 yrs (5.5–19) |
4.6 days (RUSH method) |
3 months | 5.2 g of wheat protein |
92.3 | 29.6 (up-dosing phase) |
| 5 non-anaphylactic pts | 72.4 days (outpatient method) |
2.5 (up-dosing phase) |
|||||
| Rekabi et al. 2017 [68] | 12 anaphylactic WA pts | 2.25 yrs (2–10) |
6.5 months | 18 months | 70 g spaghetties | 100 | 0.06 |
| Nowak-Wegrzyn et al. 2019 [4] | 46 WA pts (23 active group) |
8.7 yrs (4.2–22.3) |
44 weeks | 8 weeks–14 months | 4443 mg of wheat protein |
52.2 at year 1 30.4 at year 2 |
15.4% (year 1) |